Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice

J Neurochem. 2009 Nov;111(3):635-46. doi: 10.1111/j.1471-4159.2009.06314.x. Epub 2009 Jul 30.

Abstract

Fragile X syndrome (FXS), a common form of inherited mental retardation, is caused by the lack of fragile X mental retardation protein (FMRP). The animal model of FXS, Fmr1 knockout mice, have deficits in the Morris water maze and trace fear memory tests, showing impairment in hippocampus-dependent learning and memory. However, results for synaptic long-term potentiation (LTP), a key cellular model for learning and memory, remain inconclusive in the hippocampus of Fmr1 knockout mice. Here, we demonstrate that FMRP is required for glycine induced LTP (Gly-LTP) in the CA1 of hippocampus. This form of LTP requires activation of post-synaptic NMDA receptors and metabotropic glutamateric receptors, as well as the subsequent activation of extracellular signal-regulated kinase (ERK) 1/2. However, paired-pulse facilitation was not affected by glycine treatment. Genetic deletion of FMRP interrupted the phosphorylation of ERK1/2, suggesting the possible role of FMRP in the regulation of the activity of ERK1/2. Our study provide strong evidences that FMRP participates in Gly-LTP in the hippocampus by regulating the phosphorylation of ERK1/2, and that improper regulation of these signaling pathways may contribute to the learning and memory deficits observed in FXS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Amino-5-phosphonovalerate / pharmacology
  • Alanine / analogs & derivatives
  • Alanine / pharmacology
  • Analysis of Variance
  • Animals
  • Biophysics
  • Bromodeoxyuridine / metabolism
  • Butadienes / pharmacology
  • Electric Stimulation
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • Fragile X Mental Retardation Protein / genetics
  • Fragile X Mental Retardation Protein / physiology*
  • GABA Antagonists / pharmacology
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • Glycine / pharmacology
  • Glycine Agents / pharmacology
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Hippocampus / physiology*
  • In Vitro Techniques
  • Long-Term Potentiation / drug effects
  • Long-Term Potentiation / genetics
  • Long-Term Potentiation / physiology*
  • Male
  • Mice
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Nitriles / pharmacology
  • Patch-Clamp Techniques / methods
  • Picrotoxin / pharmacology
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / physiology

Substances

  • Butadienes
  • Enzyme Inhibitors
  • Excitatory Amino Acid Antagonists
  • Fmr1 protein, mouse
  • GABA Antagonists
  • Glycine Agents
  • Nitriles
  • U 0126
  • 2-amino-3-phosphonopropionic acid
  • Picrotoxin
  • Fragile X Mental Retardation Protein
  • 2-Amino-5-phosphonovalerate
  • Mitogen-Activated Protein Kinase Kinases
  • Bromodeoxyuridine
  • Alanine
  • Glycine